Exposure to rituximab did not affect ofatumumab efficacy in CLL HemOncToday Ofatumumab is active in patients with chronic lymphocytic leukemia refractory to fludarabine regardless of prior treatment with rituximab, according to the results of a phase 2 retrospective international study. Prognosis for patients with CLL who are ... |
